Gabapentin enacarbil
- Generic Name
- Gabapentin enacarbil
- Brand Names
- Horizant
- Drug Type
- Small Molecule
- Chemical Formula
- C16H27NO6
- CAS Number
- 478296-72-9
- Unique Ingredient Identifier
- 75OCL1SPBQ
- Background
Gabapentin enacarbil is marketed under the name Horizant. It is a prodrug of gabapentin, and indicated in adults for the treatment of Restless Legs Syndrome (RLS) and postherpetic neuralgia (PHN).
- Indication
For the treatment of adult Restless Legs Syndrome (RLS) and postherpetic neuralgia (PHN).
- Associated Conditions
- Postherpetic Neuralgia, Restless Legs Syndrome (RLS)
- Associated Therapies
- -
Nighttime Agitation and Restless Legs Syndrome in People With Alzheimer's Disease
- First Posted Date
- 2017-03-17
- Last Posted Date
- 2022-05-18
- Lead Sponsor
- University of Texas at Austin
- Target Recruit Count
- 156
- Registration Number
- NCT03082755
- Locations
- ๐บ๐ธ
The University of Texas at Austin, Austin, Texas, United States
A Study of Oral Dosing of Gabapentin Enacarbil in Japanese Restless Legs Syndrome Patients
- Conditions
- Interventions
- First Posted Date
- 2017-02-15
- Last Posted Date
- 2024-12-12
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 375
- Registration Number
- NCT03053427
- Locations
- ๐ฏ๐ต
Site JP00013, Shinagawa, Tokyo, Japan
๐ฏ๐ตSite JP00021, Shinjuku, Tokyo, Japan
๐ฏ๐ตSite JP00041, Kawanishi, Hyogo, Japan
Effect of Gabapentin Enacarbil on Opioid Consumption and Pain Scores
- First Posted Date
- 2016-07-21
- Last Posted Date
- 2024-01-09
- Lead Sponsor
- The Cleveland Clinic
- Target Recruit Count
- 107
- Registration Number
- NCT02840240
- Locations
- ๐บ๐ธ
Cleveland Clinic, Cleveland, Ohio, United States
The Effect of Horizant (Gabapentin Enacarbil) on Augmentation
- First Posted Date
- 2015-12-30
- Last Posted Date
- 2022-02-24
- Lead Sponsor
- University of Missouri-Columbia
- Target Recruit Count
- 10
- Registration Number
- NCT02642315
- Locations
- ๐บ๐ธ
University of Missouri Health Care, Columbia, Missouri, United States
HORIZANT (Gabapentin Enacarbil Extended-Release Tablets) for the Treatment of Alcohol Use Disorder
- First Posted Date
- 2014-09-30
- Last Posted Date
- 2018-11-14
- Target Recruit Count
- 346
- Registration Number
- NCT02252536
- Locations
- ๐บ๐ธ
The University of Texas Southwestern Medical Center, Dallas, Texas, United States
๐บ๐ธUniversity of Pennsylvania, Philadelphia, Pennsylvania, United States
๐บ๐ธUniversity of Miami, Miller School of Medicine, Miami, Florida, United States
Post-marketing Study of Gabapentin Enacarbil to Evaluate the Effect in Restless Leg Syndrome (RLS) Patients With Moderate Renal Impairment
- First Posted Date
- 2013-11-13
- Last Posted Date
- 2024-11-08
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 19
- Registration Number
- NCT01981941
Study to Assess the Effect of Gabapentin Enacarbil on Simulated Driving in Healthy Subjects
- Conditions
- Interventions
- First Posted Date
- 2011-08-08
- Last Posted Date
- 2013-07-16
- Lead Sponsor
- XenoPort, Inc.
- Target Recruit Count
- 36
- Registration Number
- NCT01411124
- Locations
- ๐บ๐ธ
GSK Investigational Site, Austin, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.